CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dengue Fever
Conditions
Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
Trial Timeline
Dec 1, 2016 → May 27, 2019
NCT ID
NCT02993757About CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
CYD Dengue Vaccine + CYD Dengue Vaccine + Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant. is a phase 3 stage product being developed by Sanofi for Dengue Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT02993757. Target conditions include Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02993757 | Phase 3 | Completed |
Competing Products
20 competing products in Dengue Fever